Accelerator recruits key personnel
Accelerators subsidiaries continue to recruit key personnel with strong industrial backgrounds. Spago Imaging has recruited Allan Simpson in Business Development and Jørgen Buus Lassen to the company’s board of directors. In Synthetic MR Johan Sedihn has joined the board of directors.
”I’m very pleased that we have managed to recruits such highly qualified personnel to our
organisation. This not only strengthens our medical competences but also the commercial
leadership in our subsidiaries. This is a strong indication that we are on the right track”, says
Andreas Bunge CEO at Accelerator.
Allan Simpson has a background from GE Healthcare where he was Director of Strategic
Alliances He was earlier Vice President for Research and Analysis and Laboratory
Separations.
Jørgen Buus Lassen D.V.M. has over 25 years experience in the field of
neuropharmacology. He is one of the founders of Neurosearch, one of Denmark’s most
successful biopharmaceutical companies.
Johan Sedihn MSc has worked at Elekta since 1993 and is chief of Elekta Oncology and
member of the executive committee. SyntheticMR will benefit from Johan’s experience of
global development of companies within the Elekta organisation.
During 2009 Spago Imaging produced their first MRI images with the SPAGO contrast
media. This new contrast media has the potential to significantly improve the visualization
and early detection of tumours.
Synthetic MR has in collaboration with Sectra started the launch of their time saving MRI
software, SyMRI Suite.
For further information, please contact:
Andreas Bunge, CEO at Accelerator Nordic AB, phone +46 70 8 24 25 25
Spago Imaging AB develops nano-particle based contrast agents for diagnostic imaging with
a focus on magnetic resonance imaging (MRI). Product development is focused on tumour
and cardiac imaging. SPAGO enables molecular imaging, providing faster imaging and
better resolution with lower dosage. For more information, please visit,
www.spagoimaging.se
SyntheticMR AB develops proprietary analytical and visualization tools enabling synthetic
MRI which help clinicians to reduce the time needed for MR-imaging dramatically, thereby
increasing patient throughput. Synthetic MR synthesizes all possible MRI parameters from a
simple general scan, eliminating the extra time needed to perform multiple scans. Other
advantages of synthetic MR are improved performance from current image analysis systems
and the possibility to analyze fewer but more precise images. For more information, please
visit, www.syntheticmr.se
Accelerator Nordic AB is a group of developing companies based on Scandinavian Life
Science. The company holds an active majority position in a number of companies providing
Pharmaceutical and Medical technology products. The Accelerator Group is addressing
therapeutics and imaging in large growth markets such as oncology, cardiology and drug
delivery for orthopedic and dental implants. Products are in clinical phase II and initial
commercialization phase. The business model is centred on partnering or out-licensing.
Accelerator Nordic is publicly traded on the Aktietorget exchange in Stockholm, Sweden.
For more information, please visit, www.acceleratorab.se
